KGA-2727 is a selective, high-affinity, orally active sodium-glucose cotransporter 1 (SGLT1) inhibitor used in preclinical research. It competitively inhibits human and rat SGLT1 (Ki 97.4 nM and 43.5 nM, respectively), shows substantial selectivity over SGLT2, and has demonstrated glucose-lowering efficacy in animal diabetes models.
- Selective SGLT1 inhibition with competitive mechanism.
- High affinity for human and rat SGLT1 (Ki ~97.4 nM and 43.5 nM).
- Demonstrated glucose-lowering activity in preclinical diabetic models.
- High reported purity suitable for research use.
- Good solubility in DMSO and ethanol; moderate solubility in water with warming.
- Solid form with defined storage recommendations for stability.